Status:

WITHDRAWN

Efficacy of BACMUNE (MV130) in the Prevention of Disease Due to COVID-19 Infection in Healthcare Personnel

Lead Sponsor:

Inmunotek S.L.

Conditions:

Covid19

Eligibility:

All Genders

18-65 years

Phase:

PHASE3

Brief Summary

The purpose of this trial is to assess the effect of immunotherapy with the bacterial preparation MV130 on the spread and course of SARS-CoV-2 infection in highly exposed subjets, as is the case with ...

Detailed Description

This is a prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial to assess the efficacy of BACMUNE (MV130) in the prevention of disease due to SARS-VoC-2 infection in he...

Eligibility Criteria

Inclusion

  • Health personnel who are or have been in contact with patients with disease due to SARS-COV-2 infection within the last 14 days before randomization.
  • Negative result for test against COVID-19.
  • Subjects who have given informed consent.
  • Men or women aged between 18 and 65 years, both included.
  • Subjects who have a smartphone where they can load an APP for monitoring the symptoms.

Exclusion

  • Subjects who are participating in another clinical trial.
  • Subjects who are unable to offer cooperation and/or have serious psychiatric disorders.
  • Subjects who are allergic to any of the compounds included into MV130.
  • Subjects who present contraindications to any of the components of BACMUNE (MV130).
  • Subjects who are not able to comply with the dosage regimen.
  • Subjects with immunodeficiencies.
  • Subjects with malignancy involving the bone marrow or lymphoid systems.
  • Pregnant or suspected pregnant women and breastfeeding women.
  • Subjects in medical treatment that affects the response of the immune system. It includes corticosteroids (equal to or more than 20 mg for more than 2 weeks), immunosuppressants, biological agents (such as anti TNF-alpha monoclonal antibodies, etc.).
  • Subjects with HIV.
  • Subjects under treatment with metformin.
  • Subjects treated with Sertraline.
  • Subjects treated with statins.

Key Trial Info

Start Date :

October 1 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2021

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT04452643

Start Date

October 1 2020

End Date

December 1 2021

Last Update

November 2 2020

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

Instituto Nacional de Enfermedades Respiratorias (INER)

Mexico City, Mexico, Ciudad de México

2

Hospital General de Pachuca

Pachuca, Mexico, 42070

3

Hospital de Ciudad Valles

San Luis Potosí City, Mexico